134 related articles for article (PubMed ID: 35410754)
1. A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib.
Cohen-Rabbie S; Mattinson A; So K; Wang N; Goldwater R
Clin Ther; 2022 Apr; 44(4):565-576. PubMed ID: 35410754
[TBL] [Abstract][Full Text] [Related]
2. Effect of food on capsule and granule formulations of selumetinib.
Cohen-Rabbie S; Mattinson A; So K; Wang N; Goldwater R
Clin Transl Sci; 2022 Apr; 15(4):878-888. PubMed ID: 35170228
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
[TBL] [Abstract][Full Text] [Related]
4. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies.
Manitpisitkul P; Shalayda K; Russell L; Sanga P; Williams Y; Solanki B; Caruso J; Moyer JA
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):699-711. PubMed ID: 29125700
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
Naing A; Kurzrock R; Adams LM; Kleha JF; Laubscher KH; Bonate PL; Weller S; Fitzgerald C; Xu Y; LoRusso PM
Invest New Drugs; 2012 Feb; 30(1):327-34. PubMed ID: 20842406
[TBL] [Abstract][Full Text] [Related]
9. Setipiprant, a selective oral antagonist of human CRTH2: relative bioavailability of a capsule and a tablet formulation in healthy female and male subjects.
Baldoni D; Mackie A; Gutierrez M; Theodor R; Dingemanse J
Clin Ther; 2013 Nov; 35(11):1842-8. PubMed ID: 24095247
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
Cohen-Rabbie S; Zhou L; Vishwanathan K; Wild M; Xu S; Freshwater T; Jain L; Schalkwijk S; Tomkinson H; Zhou D
J Clin Pharmacol; 2021 Nov; 61(11):1493-1504. PubMed ID: 34196005
[TBL] [Abstract][Full Text] [Related]
11. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study.
Li KY; Liang JP; Hu BQ; Qiu Y; Luo CH; Jiang Y; Lin XP; Yang N
Clin Ther; 2010 Aug; 32(9):1674-80. PubMed ID: 20974325
[TBL] [Abstract][Full Text] [Related]
12. Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects.
Qian H; Wu X; Chen Q; Li T; Wang W; Jia J; Yu C; Li K; Sai Y; Su W; Liu Y
Clin Ther; 2020 Sep; 42(9):1778-1786. PubMed ID: 32800383
[TBL] [Abstract][Full Text] [Related]
13. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
Suenobu S; Terashima K; Akiyama M; Oguri T; Watanabe A; Sugeno M; Higashimori M; So K; Nishida Y
Neurooncol Adv; 2023; 5(1):vdad054. PubMed ID: 37287695
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.
Liu MY; Wang S; Yao WF; Wu HZ; Meng SN; Wei MJ
Clin Ther; 2009 Apr; 31(4):784-92. PubMed ID: 19446151
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
Sikes C; Stark JG; McMahen R; Engelking D
Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
[TBL] [Abstract][Full Text] [Related]
16. Relative bioavailability of levodropropizine 60 mg capsule and syrup formulations in healthy male Korean volunteers: a singledose, randomized-sequence, open-label, two-way crossover study.
Jang JW; Seo JH; Jo MH; Lee YJ; Cho YW; Yim SV; Lee KT
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):152-60. PubMed ID: 23351597
[TBL] [Abstract][Full Text] [Related]
17. An open-label, phase 1, randomized, three treatments, three-period, crossover, relative bioavailability study of CC-292, a potent and orally available inhibitor of bruton tyrosine kinase.
Cheng Y; Liu L; Xue Y; Zhou S; Li Y
J Clin Pharm Ther; 2022 Aug; 47(8):1186-1193. PubMed ID: 35307850
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
[TBL] [Abstract][Full Text] [Related]
19. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
[TBL] [Abstract][Full Text] [Related]
20. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Leijen S; Soetekouw PM; Jeffry Evans TR; Nicolson M; Schellens JH; Learoyd M; Grinsted L; Zazulina V; Pwint T; Middleton M
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1619-28. PubMed ID: 21953275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
